HHS, DOD collaborate to produce COVID-19 vaccines, therapeutics

The Department of Health and Human Services and Department of Defense today announced a $1.6 billion agreement to demonstrate commercial-scale manufacturing of Novavax, Inc.’s investigational COVID-19 vaccine. By funding this manufacturing effort, the federal government will own the 100 million vaccine doses produced through the demonstration.

HHS and DOD today also announced a similar agreement with Regeneron Inc. to demonstrate manufacturing of an investigational COVID-19 antiviral treatment. Under the agreement, the company said the U.S. could own between 70,000 and 300,000 doses of the therapeutic.